Skip to main content

Table 1 Questions and options included in the electronic data collection tool

From: The perplexity of prescribing and switching of biologic drugs in rheumatoid arthritis: a UK regional audit of practice

1. Demographic data
Hospital unit:
Burton, Cannock, Birmingham City Hospital, Coventry, Derby, Dudley, Hereford, Kings Mill, Leicester, Lincoln, Northampton, Nottingham, Shrewsbury, Solihull, Stoke, University Hospital Birmingham, Warwick, Wolverhampton, Worcester
Hospital ID number:
Date of birth:
Gender:
Male, female
Rheumatoid factor status:
Positive, negative, unknown
Anti-CCP status:
Positive, negative, unknown
How many times did the patient switch (change) their biologic drug in 2011?
1, 2, 3, more than 3
2. Biologic drug being switched to:
Abatacept, Adalimumab, Certolizumab, Etanercept, Golilumab, Infliximab, Rituximab, Tocilizumab
3. Biologic drug being switched from:
Abatacept, Adalimumab, Certolizumab, Etanercept, Golilumab, Infliximab, Rituximab, Tocilizumab
4. Why was the biologic drug in 2. chosen?
Departmental protocol, risk of tuberculosis/other infection, commissioning restriction, patient choice, research participation, pharmaceutical incentive, physician’s choice
5. Why was the biologic drug in 3. discontinued?
End of trial, lack of effect, intolerance/adverse event, drug site reaction, cardiac side effects, respiratory side effects, malignancy, neuropathy, demyelination, tuberculosis, septic arthritis, other infection
6. Did the patient continue with the biologic drug in 2. for the next six months?
Yes, no
If Yes, did the DAS-28 score meet NICE response criteria?
Yes, no, not assessed
7. Was concomitant Methotrexate used?
Yes, No
If No, what was the reason for not using?
Free text
8. Other concomitant DMARDs used at the time of the drug switch:
Azathioprine, Ciclosporin, Corticosteroids, Cyclophosphamide, Gold, Hydroxychloroquine, Leflunomide, Penicillamine, Sulfasalazine, Other
9. Repeat steps 2. To 8. with successive switches
10. Biologic drugs used pre-2011:
Abatacept, Adalimumab, Certolizumab, Etanercept, Golilumab, Infliximab, Rituximab, Tocilizumab